06 February 2024 : Original article
Immunoprotective Effect of Liver Allograft on Patients with Combined Liver and Kidney Transplantation
Joon-Young Kim
1BCDEF, Hye Bin Kim2BCDEF, Jin-Myung Kim 1BCD, Hye Eun Kwon 1BCD, Young Hoon Kim 1BCD, Youngmin Ko 1BCD, Frances S. Sung 1BCD, Joo Hee Jung 1BC, Chung Hee Baek 3B, Hyosang Kim 3B, Su-Kil Park 3B, Sung Shin 1BCD, Hyunwook Kwon1ABCDEF*
DOI: 10.12659/AOT.942763
Ann Transplant 2024; 29:e942763
Table 1 Baseline and clinical characteristics of the study patients.
| Total | KT | LTKT | P-value | |
|---|---|---|---|---|
| Number of patients | 4312 (100) | 4268 (99.0) | 44 (1.0) | – |
| Mean age (years) | 47.0±12.4 | 47.0±12.4 | 40.2±8.2 | 0.090 |
| Female sex | 1814 (42.1) | 1807 (42.3) | 7 (15.9) | <0.001 |
| Diabetes mellitus | 1034 (24.0) | 1018 (23.9) | 16 (36.4) | 0.053 |
| Hypertension | 3637 (84.3) | 3605 (84.5) | 32 (72.7) | 0.033 |
| Hepatitis B virus | 144 (3.3) | 132 (3.1) | 12 (27.3) | <0.001 |
| Hepatitis C virus | 79 (1.8) | 78 (1.8) | 1 (2.3) | 0.827 |
| Body mass index, Kg/m | 23.4±39.9 | 23.4±40.1 | 22.0±2.7 | 0.819 |
| ABO incompatible | 735 (14.6) | 730 (14.6) | 5 (11.4) | 0.542 |
| FCXM positive | 261 (6.1) | 259 (6.1) | 2 (4.5) | 0.673 |
| HLA-A, B, DR mismatch | 3.2±1.7 | 3.2±1.7 | 3.5±1.9 | 0.168 |
| PRA class I | 13.4±25.8 | 13.1±25.8 | 11.3±24.2 | 0.627 |
| PRA class II | 15.2±27.6 | 15.2±27.6 | 13.4±26.7 | 0.773 |
| Cadaveric donor | 857 (19.9) | 844 (19.8) | 13 (29.5) | 0.106 |
| Living donor | 3455 (80.1) | 3424 (80.2) | 31 (70.5) | |
| Calcineurin inhibitor | 0.924 | |||
| Tacrolimus | 3306 (76.7) | 3272 (76.7) | 34 (77.3) | |
| Cyclosporin | 1006 (23.3) | 996 (23.3) | 10 (22.7) | |
| Induction | 0.29 | |||
| Basiliximab | 3919 (90.9) | 3877 (90.9) | 42 (95.5) | |
| Anti-thymocyte globulin | 391 (9.1) | 389 (9.1) | 2 (4.5) | |
| SLKT | 11 (25.0) | – | ||
| KT after LT | 33 (75.0) | |||
| Continuous data are presented as means±standard deviations. Categorical data are presented as a number (%).KT – kidney transplantation; LT – liver transplantation; FCXM – flow cytometry crossmatch; DSA – donor-specific antibody; PRA – panel reactive antibody; SLKT – simultaneous liver-kidney transplantation. | ||||